Nivalis posts $31.5M loss for 2016; staff reduction continues

Facebook Twitter Google+ LinkedIn Email Print  BOULDER — Nivalis Therapeutics Inc., a biopharmaceutical company based in Boulder that is developing treatments for cystic fibrosis, on Monday reported a loss of $31.5 million for its fiscal year that ended Dec. 31, and is continuing its staff reduction as it winds down research-and-development activities. The job cuts are affecting 25 employees, including Jon Congleton, the company’s former president and chief executive, and Dr. David Rodman, the company’s…